Overview

AK104 in Neoadjuvant Treatment of Cervical Cancer

Status:
Not yet recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

Phase II open label study to evaluate the safety and efficacy of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Akeso